Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.

Publication Type:

Journal Article

Source:

Cancer, Volume 113, Issue 6, p.1370-8 (2008)

Keywords:

Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Child, Cytarabine, Daunorubicin, Disease-Free Survival, Female, Humans, Idarubicin, Leukemia, Myeloid, Acute, Male, Middle Aged, Remission Induction, Sarcoma, Myeloid, Survival Rate, Treatment Outcome

Abstract:

It is unknown whether patients with nonleukemic myeloid sarcoma (MS) and those with acute myeloid leukemia (AML) have similar responses to anti-AML treatment. In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes.